Vispi Martina, Corradin Teresa, Peccianti Camilla, Feci Luca, Casini Laura, Pisani Chiara, Fabbroni Susanna, Corsetti Paola, Croatto Margherita, Pellegrino Michele
Dermatology Unit, Misericordia Hospital, Grosseto.
Dermatology Unit, Pordenone Hospital, Pordenone, Italy.
Dermatol Reports. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642.
On January 30, 2020, World Health Organization (WHO) stated that a new coronavirus disease outbreak [COronaVIrus Disease - 19 (COVID-19)] was an international public health emergency. Many news, often fake ones, about the derived pandemic rapidly spread along the media, thus leading many dermatological patients to identify as "risk category" and sometimes discontinue treatments by themselves. The Dermatology Units in Grosseto and Pordenone simultaneously carried out a data collection by remote-conducted visits, evaluating the incidence of COVID-19 in psoriatic patients. Only 1 patient (close contact of a case) as part of the psoriasis analyzed group was tested and turned out to be positive for SARS-CoV-2, developing no symptoms during the observation period. The collected information may suggest that psoriasis, biotechnologically treated or not, cannot promote or aggravate the clinical trend of the SARS-CoV-2 infection, hence stopping systemic therapy in negative or clinically free SARS-CoV-2 patients is not recommended in general.
2020年1月30日，世界卫生组织（WHO）宣布新型冠状病毒疾病爆发[冠状病毒病-19（COVID-19）]为国际公共卫生紧急事件。许多关于这场衍生大流行的新闻，其中不乏虚假新闻，迅速在媒体上传播，导致许多皮肤科患者将自己视为“风险类别”，有时甚至自行中断治疗。格罗塞托和波代诺内的皮肤科科室同时通过远程问诊进行数据收集，评估银屑病患者中COVID-19的发病率。在分析的银屑病患者组中，只有1名患者（一名病例的密切接触者）接受了检测，结果显示其感染了SARS-CoV-2，但在观察期内未出现症状。收集到的信息表明，无论是否接受生物技术治疗，银屑病都不会促进或加重SARS-CoV-2感染的临床进程，因此一般不建议在SARS-CoV-2检测呈阴性或临床上无症状的患者中停止全身治疗。
